Literature DB >> 11226460

The use of post-source decay in matrix-assisted laser desorption/ionisation mass spectrometry to delineate T cell determinants.

A W Purcell1, J J Gorman.   

Abstract

The identification of naturally processed peptides presented by molecules of the major histocompatibility complex (MHC) has progressed significantly over the past decade. The elution of peptides from immunoaffinity purified complexes of MHC class I or class II molecules has provided highly specific biochemical information regarding the nature of endogenous peptides capable of binding to and being presented by particular MHC alleles. Whilst Edman chemistry is sufficient for the identification of abundant or homogeneous immunodominant peptides contained in samples of fractionated peptides, mass spectrometry has proved more powerful for sequencing less abundant species present in the typically heterogeneous fractions of eluted peptides. This review focuses on the characterisation of T cell determinants by matrix-assisted laser desorption/ionisation (MALDI)-time-of-flight (TOF) mass spectrometry (MS). We demonstrate, with specific examples, the utility of post-source decay in MALDI-TOF MS for the characterisation of the amino acid sequences of both native and modified T cell determinants. The potential advantages and pitfalls of this technique relative to the more commonly used forms of tandem mass spectrometry in electrospray and ion spray modes of ionisation as well as hybrid quadrupole-quadrupole-TOF instruments are discussed. We highlight the complementarity between these techniques and discuss the advantages in the combined use of both MALDI- and electrospray-based instrumentation in epitope identification strategies.

Mesh:

Year:  2001        PMID: 11226460     DOI: 10.1016/s0022-1759(00)00361-6

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Using oxidized carbon nanotubes as matrix for analysis of small molecules by MALDI-TOF MS.

Authors:  Chensong Pan; Songyun Xu; Ligang Hu; Xingye Su; Junjie Ou; Hanfa Zou; Zhong Guo; Yu Zhang; Baochuan Guo
Journal:  J Am Soc Mass Spectrom       Date:  2005-04-15       Impact factor: 3.109

Review 2.  Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.

Authors:  Gabor Mester; Vanessa Hoffmann; Stefan Stevanović
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

3.  MHC-I peptides get out of the groove and enable a novel mechanism of HIV-1 escape.

Authors:  Phillip Pymm; Patricia T Illing; Sri H Ramarathinam; Geraldine M O'Connor; Victoria A Hughes; Corinne Hitchen; David A Price; Bosco K Ho; Daniel W McVicar; Andrew G Brooks; Anthony W Purcell; Jamie Rossjohn; Julian P Vivian
Journal:  Nat Struct Mol Biol       Date:  2017-02-20       Impact factor: 15.369

4.  The utility and limitations of current Web-available algorithms to predict peptides recognized by CD4 T cells in response to pathogen infection.

Authors:  Francisco A Chaves; Alvin H Lee; Jennifer L Nayak; Katherine A Richards; Andrea J Sant
Journal:  J Immunol       Date:  2012-03-30       Impact factor: 5.422

5.  Proteomics in Vaccinology and Immunobiology: An Informatics Perspective of the Immunone.

Authors:  Irini A. Doytchinova; Paul Taylor; Darren R. Flower
Journal:  J Biomed Biotechnol       Date:  2003

6.  Constitutive and inflammatory immunopeptidome of pancreatic β-cells.

Authors:  Nadine L Dudek; Chor Teck Tan; Dhana G Gorasia; Nathan P Croft; Patricia T Illing; Anthony W Purcell
Journal:  Diabetes       Date:  2012-08-07       Impact factor: 9.461

7.  A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition.

Authors:  Whitney A Macdonald; Anthony W Purcell; Nicole A Mifsud; Lauren K Ely; David S Williams; Linus Chang; Jeffrey J Gorman; Craig S Clements; Lars Kjer-Nielsen; David M Koelle; Scott R Burrows; Brian D Tait; Rhonda Holdsworth; Andrew G Brooks; George O Lovrecz; Louis Lu; Jamie Rossjohn; James McCluskey
Journal:  J Exp Med       Date:  2003-08-25       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.